B.BRAUN Omnitest~电子感应血糖仪临床验证报告

糖尿病代谢控制的重要内容为血糖监测 ,由于其直接关系到糖尿病的治疗 ,因此测血糖方法的准确性和便利程度一直是临床医生十分关注的问题。本文对 B.BRAUN Omnitest○R电子感应血糖仪的精确性进行了评估 ,探讨其精确性和准确性。方法一、试验材料血糖标本来源 :全部标本取自来门诊就诊的 2型糖尿病病人 10 0例 ,事先征得病人同意。全部患者采空腹血 ,其中 5 0例同时采餐后 2小时血 ,将静脉血标本置于氟化钠抗凝管中 ,用葡萄糖氧化酶法在生化分析仪上测定静脉血浆血糖 (VPG)。同时立即采受试者毛细血管血一滴 ,用 B.BRAU N Omnitest…     

自身免疫性甲状腺损害与甲状腺功能减退症

自身免疫性甲状腺损害与甲状腺功能减退症高妍甲状腺功能减退症（甲减）是较常见的内分泌疾病，由各种原因引起甲状腺激素分泌不足，血中甲状腺激素水平减低或靶器官对其拮抗而引起。绝大多数是因甲状腺本身损害所致原发性甲减，少数是由垂体或下丘脑疾病引起的继发性甲减...     

不同糖耐量人群胰岛素抵抗和胰岛β细胞功能减退的差异

目的探讨不同糖耐量人群胰岛素抵抗（IR）和胰岛B细胞功能状态。方法分析5523例患者行OGTT和胰岛素释放试验的结果，根据WHO标准将研究对象分为糖代谢正常（NGT）组、单纯空腹血糖升高（IFG）组、单纯糖耐量减低（IGT）组、空腹血糖升高合并糖耐量受损（IFG＋IGT）组和2型糖尿病（T2DM）组。结果（1）HOMA-IR：IFG、IGT、IFG＋IGT和T2DM组比NGT组分别增加41％、19％、47％和69％（P〈0．01）。（2）校正IR影响后，IFG、IGT、IFG＋IGT和T2DM组比NGT组HOMA-β分别下降54％、19％、55％和68％，△I30/△G30分别下降47％、40％、63％和82％（P〈0．001）；IFG、IFG＋IGT和T2DM组AUCI比NGT组分别下降27％、26％和30％（P〈0．01）。结论（1）从IGT、IFG、IFG＋IGT到T2DM发展过程中IR程度逐渐加重，胰岛β细胞早时相分泌和基础分泌功能逐渐衰竭，晚时相分泌代偿能力功能减弱，总体分泌功能逐渐减退。（2）从NGT、IGT、IFG、IFG＋IGT到T2DM的糖代谢异常发生发展过程反映了胰岛β细胞早时相、基础和整体分泌功能逐渐衰退变化规律。     

甲状腺机能亢进性心脏病

甲状腺机能亢进(下称甲亢)时心脏的改变比较明显。由于甲状腺激素直接作用于心肌,可增加心肌组织中Na~+—K~+—ATP酶及肌球蛋白ATP酶活性,兴奋心肌腺苷环化酶,降低心脏对迷走神经刺激的敏感性,增加肾上腺素能交感活动,故可使心串加快,心肌收缩力加强,心搏出量增加,心脏指数常达5～7 L/(min·m~2),外周血管阻力下降。为适应上述代谢的需要,增加周围组织供氧,临床     

氨茶碱致心律失常36例分析

氨茶碱因其显著扩张支气管、增加心肌收缩力及利尿作用而广泛地在临床使用，用于治疗气管炎、支气管炎、哮喘、心力衰竭等，取得良好临床治疗效果和临床经济效益。     

丙基硫氧嘧啶对甲状腺功能亢进症患者血清甲状腺激素水平的影响

本文报告29例甲亢患者一次顿服PTU 200mg后血清甲状腺激素水平的急性变化,及15例患者日服PTU 300mg连续4周后血清甲状腺激素水平的慢性变化。并以Methimazole为对照进行比较,探讨了PTU急性和慢性作用的机理及临床实用意义。本研究结果表明,PTU可能通过对5＇脱碘酶的抑制,减少外周组织T_4转换成T_3,迅速控制血清中生物活性较强的T_3水平,在严重甲亢或甲亢危象时应首先选用。PTU及Methimazole长期应用均可使血清甲状腺激素水平显著下降,且两药效果无明显差别。     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.